



**HAL**  
open science

# **A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study**

Jakub G. Sobiecki, Fumiaki Imamura, Courtney Rose Davis, Stephen John Sharp, Albert Koulman, Jonathan M. Hodgson, Marcela M. Guevara, Matthias Bernd Schulze, Jusheng Zheng, Claudia Agnoli, et al.

## **► To cite this version:**

Jakub G. Sobiecki, Fumiaki Imamura, Courtney Rose Davis, Stephen John Sharp, Albert Koulman, et al.. A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study. *PLoS Medicine*, 2023, 20 (4), 10.1371/journal.pmed.1004221 . hal-04233250

**HAL Id: hal-04233250**

**<https://hal.science/hal-04233250>**

Submitted on 18 Oct 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH ARTICLE

# A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study



Jakub G. Sobiecki<sup>1</sup>, Fumiaki Imamura<sup>1</sup>, Courtney R. Davis<sup>1,2</sup>, Stephen J. Sharp<sup>1</sup>, Albert Koulman<sup>1,3</sup>, Jonathan M. Hodgson<sup>4,5</sup>, Marcela Guevara<sup>6,7,8</sup>, Matthias B. Schulze<sup>9,10,11</sup>, Ju-Sheng Zheng<sup>1,12</sup>, Claudia Agnoli<sup>13</sup>, Catalina Bonet<sup>14,15</sup>, Sandra M. Colorado-Yohar<sup>7,16,17</sup>, Guy Fagherazzi<sup>18,19</sup>, Paul W. Franks<sup>20</sup>, Thomas E. Gundersen<sup>21</sup>, Franziska Jannasch<sup>9,10</sup>, Rudolf Kaaks<sup>22</sup>, Verena Katzke<sup>22</sup>, Esther Molina-Montes<sup>7,23,24,25</sup>, Peter M. Nilsson<sup>20</sup>, Domenico Palli<sup>26</sup>, Salvatore Panico<sup>27</sup>, Keren Papier<sup>28</sup>, Olov Rolandsson<sup>29</sup>, Carlotta Sacerdote<sup>30</sup>, Anne Tjønneland<sup>31,32</sup>, Tammy Y. N. Tong<sup>27</sup>, Yvonne T. van der Schouw<sup>33</sup>, John Danesh<sup>34,35,36,37,38</sup>, Adam S. Butterworth<sup>34,35</sup>, Elio Riboli<sup>39</sup>, Karen J. Murphy<sup>2</sup>, Nicholas J. Wareham<sup>1</sup>, Nita G. Forouhi<sup>1</sup>\*

**OPEN ACCESS**

**Citation:** Sobiecki JG, Imamura F, Davis CR, Sharp SJ, Koulman A, Hodgson JM, et al. (2023) A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study. *PLoS Med* 20(4): e1004221. <https://doi.org/10.1371/journal.pmed.1004221>

**Academic Editor:** Barry M. Popkin, Carolina Population Center, UNITED STATES

**Received:** September 2, 2022

**Accepted:** March 15, 2023

**Published:** April 27, 2023

**Copyright:** © 2023 Sobiecki et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Data from the MedLey trial contains sensitive participant information. For data access, please contact the University of South Australia Human Research Ethics Committee at [humanethics@unisa.edu.au](mailto:humanethics@unisa.edu.au) or [researchintegrity@unisa.edu.au](mailto:researchintegrity@unisa.edu.au). EPIC-InterAct Study data cannot be deposited publicly as these collaborative data originate from multiple research institutions across eight European countries with different legal frameworks. The authors confirm

**1** MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United Kingdom, **2** Alliance for Research in Exercise, Nutrition and Activity, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia, **3** Nutritional Biomarker Laboratory, National Institute for Health Research Biomedical Research Centre, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, **4** Nutrition & Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, **5** Medical School, University of Western Australia, Perth, Australia, **6** Navarra Public Health Institute, Pamplona, Spain, **7** CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain, **8** Navarra Institute for Health Research (IdiSNA), Pamplona, Spain, **9** Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany, **10** German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany, **11** Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany, **12** Key Laboratory of Growth Regulation and Translation Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China, **13** Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy, **14** Unit of Nutrition and Cancer, Catalan Institute of Oncology—ICO, L'Hospitalet de Llobregat, Barcelona, Spain, **15** Nutrition and Cancer Group, Bellvitge Biomedical Research Institute—IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, **16** Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain, **17** Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia, **18** Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg, **19** Center of Epidemiology and Population Health UMR 1018, Inserm, Paris South—Paris Saclay University, Gustave Roussy Institute, Villejuif, France, **20** Department of Clinical Sciences, Lund University, Malmö, Sweden, **21** Vitas AS, Oslo, Norway, **22** Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, **23** Institute of Nutrition and Food Technology (INYTA) 'José Mataix', Biomedical Research Centre, University of Granada, Granada, Spain, **24** Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain, **25** Department of Nutrition and Food Science, University of Granada, Granada, Spain, **26** Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network—ISPRO, Florence, Italy, **27** Department of Mental, Physical Health and Preventive Medicine, University "L. Vanvitelli", Naples, Italy, **28** Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, **29** Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden, **30** Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin, Italy, **31** Danish Cancer Society Research Center, Copenhagen, Denmark, **32** Department of Public Health, University of Copenhagen, Copenhagen, Denmark, **33** Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, **34** BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, **35** NIHR Blood and Transplant

that researchers seeking the analysis dataset for this work can submit a data request to the EPIC-InterAct study central contact point by emailing [interact@mrc-epid.cam.ac.uk](mailto:interact@mrc-epid.cam.ac.uk).

**Funding:** The MedLey trial was funded by a National Health and Medical Research Council Grant (#APP1050949 to KJM). The InterAct project was funded by the EU FP6 programme (grant number LSHM\_CT\_2006\_037197 to NJW). Biomarker measurements for carotenoids were funded jointly by the InterAct project, the EPIC-CVD project, and the MRC Cambridge Initiative (RG71466 and SJAH/004 to NJW, NGF, JD, AB). EPIC-CVD has been supported by the UK Medical Research Council (MR/L003120/1 to ASB and JD), the British Heart Foundation (RG/13/13/30194 and RG/18/13/33946 to ASB and JD), the European Commission Framework Programme 7 (HEALTH-F2-2012-279233 to ASB and JD), the European Research Council (268834 to ASB and JD), and the National Institute for Health Research (NIHR; Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust, BRC-1215-20014 to ASB and JD). This work was also supported by Health Data Research UK (to ASB and JD), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), and Wellcome. The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Iblea Ricerca Epidemiologica (A.I.R.E. – ONLUS) Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di San Paolo, National Research Council and Sicilian Regional Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands

Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, **36** British Heart Foundation Cambridge Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom, **37** Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom, **38** Health Data Research UK Cambridge, University of Cambridge, Cambridge, United Kingdom, **39** School of Public Health, Imperial College London, London, United Kingdom

☯ These authors contributed equally to this work.

\* [nita.forouhi@mrc-epid.cam.ac.uk](mailto:nita.forouhi@mrc-epid.cam.ac.uk)

## Abstract

### Background

Self-reported adherence to the Mediterranean diet has been modestly inversely associated with incidence of type 2 diabetes (T2D) in cohort studies. There is uncertainty about the validity and magnitude of this association due to subjective reporting of diet. The association has not been evaluated using an objectively measured biomarker of the Mediterranean diet.

### Methods and findings

We derived a biomarker score based on 5 circulating carotenoids and 24 fatty acids that discriminated between the Mediterranean or habitual diet arms of a parallel design, 6-month partial-feeding randomised controlled trial (RCT) conducted between 2013 and 2014, the MedLey trial (128 participants out of 166 randomised). We applied this biomarker score in an observational study, the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, to assess the association of the score with T2D incidence over an average of 9.7 years of follow-up since the baseline (1991 to 1998). We included 22,202 participants, of whom 9,453 were T2D cases, with relevant biomarkers from an original case-cohort of 27,779 participants sampled from a cohort of 340,234 people. As a secondary measure of the Mediterranean diet, we used a score estimated from dietary-self report. Within the trial, the biomarker score discriminated well between the 2 arms; the cross-validated C-statistic was 0.88 (95% confidence interval (CI) 0.82 to 0.94). The score was inversely associated with incident T2D in EPIC-InterAct: the hazard ratio (HR) per standard deviation of the score was 0.71 (95% CI: 0.65 to 0.77) following adjustment for sociodemographic, lifestyle and medical factors, and adiposity. In comparison, the HR per standard deviation of the self-reported Mediterranean diet was 0.90 (95% CI: 0.86 to 0.95). Assuming the score was causally associated with T2D, higher adherence to the Mediterranean diet in Western European adults by 10 percentiles of the score was estimated to reduce the incidence of T2D by 11% (95% CI: 7% to 14%). The study limitations included potential measurement error in nutritional biomarkers, unclear specificity of the biomarker score to the Mediterranean diet, and possible residual confounding.

### Conclusions

These findings suggest that objectively assessed adherence to the Mediterranean diet is associated with lower risk of T2D and that even modestly higher adherence may have the potential to reduce the population burden of T2D meaningfully.

Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to NJW; C8221/A29017), Medical Research Council (1000143 to NJW; MR/M012190/1) (United Kingdom). JGS was supported by the MRC PhD studentship. NJW, NGF, and FI acknowledge funding from the Medical Research Council Epidemiology Unit (MC\_UU\_00006/1, MC\_UU\_00006/3); and NJW, NGF and AK from the NIHR Cambridge Biomedical Research Centre (IS-BRC-1215-20014; NIHR203312). NGF and JD are NIHR Senior Investigators. JD holds a British Heart Foundation Professorship. MBS acknowledges funding from the Federal Ministry of Education and Research and the State of Brandenburg (DZD grant 82DZD03D03). JSZ has received funding from Westlake University (No YSYY0209) and European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 701708. PWF has received funding from Novo Nordisk, Swedish Diabetes Association, Swedish Heart-Lung Foundation, European Research Council. ER has received funding from Imperial College Biomedical Research Centre. The funders of the studies had no role in the study design, data collection, data analysis, data interpretation, or report preparation.

**Competing interests:** I have read the journal's policy and the authors of this manuscript have the following competing interests: Authors declare support from the UK Medical Research Council, British Heart Foundation, Wellcome Trust, European Research Council, Swedish Research Council and National Institute for Health Research Cambridge Biomedical Research Centre for the submitted work. FI is a member of PLOS Medicine's editorial board. PWF reports support for the submitted work from Novo Nordisk Foundation and consulting for Zoe Limited. JD reports grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees and non-financial support from Novartis, grants from Pfizer and grants from AstraZeneca outside the submitted work. JD sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011);

## Trial registration

Australian New Zealand Clinical Trials Registry (ANZCTR) [ACTRN12613000602729](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363860)  
<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363860>.

## Author summary

### Why was this study done?

- Epidemiological evidence has indicated that greater self-reported adherence to the Mediterranean diet may be associated with lower risk of new onset type 2 diabetes (T2D), but there has been uncertainty about the magnitude of association due to subjective reporting of diet.
- A combination of nutritional biomarkers could better assess diet–disease associations, but this approach has rarely been considered for overall diet quality, particularly for the association between the Mediterranean diet and T2D.

### What did the researchers do and find?

- Blood carotenoids and fatty acids can be used as an objective measure of adherence to the Mediterranean diet, as indicated by results from a trial ( $n = 128$ ) of adopting Mediterranean diet with provision of its key foods to study participants. These biomarkers discriminated well between the trial participants under the Mediterranean diet intervention and those randomised to continuation of habitual diet ( $C$ -statistic = 0.88).
- In a study across 8 European countries ( $n = 22,202$ ), adherence to the Mediterranean diet, estimated using a combination of nutritional biomarkers, was associated with lower risk of new onset T2D, with a stronger relationship compared to that with self-reported Mediterranean diet. The hazard ratios (HRs) (95% confidence interval (CI)) per standard deviation of adherence were 0.71 (0.65 to 0.77) and 0.90 (0.86 to 0.95), respectively.

### What do these findings mean?

- Adherence to the Mediterranean diet may be more beneficial for the primary prevention of T2D than previously estimated from observational dietary studies.
- Even small upward differences in objectively measured Mediterranean diet may be associated with a sizeable reduction of the risk of T2D at the population level.
- Causal interpretation of these findings is limited by potential measurement error in nutritional biomarkers, unclear specificity of the biomarker score to the Mediterranean diet, and possible residual confounding.

the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science 'Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the AstraZeneca Genomics Advisory Board (2018). ASB reports institutional grants outside the submitted work from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis and Sanofi. Authors otherwise report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work.”

**Abbreviations:** CI, confidence interval; EPIC, European Prospective Investigation into Cancer and Nutrition; HPLC, high-performance liquid chromatography; HR, hazard ratio; IQR, interquartile range; PAF, population attributable fraction; RCT, randomised controlled trial; SD, standard deviation; TC, total cholesterol; T2D, type 2 diabetes.

## Introduction

The Mediterranean diet is a dietary pattern typically characterised by high consumption of vegetables, legumes, fruit, nuts, grains, fish and seafood, virgin olive oil, and moderate intake of meat, dairy, and wine. It has been reported to be associated with decreased incidence of multiple noncommunicable diseases including type 2 diabetes (T2D) [1,2]. However, the evidence on the Mediterranean diet for prevention of T2D stems predominantly from observational research using self-reported dietary assessment, with modest effect sizes [3]. Dietary self-report is subject to systematic and random measurement error that may bias the associations with disease risk in an unknown direction [4]. Thus, the relationship between the Mediterranean diet and the incidence of T2D may have been misquantified. Uncertainty about the validity and size of this association limits robustness of the evidence for this dietary pattern and T2D incidence [3].

Nutritional biomarkers can complement the self-reported assessment of habitual dietary exposure. Dietary patterns, however, lack biologically plausible single biomarkers and, therefore, necessitate combining multiple analytes into composite biomarker scores [5,6]. Research on the derivation of such a score of the Mediterranean diet has had a number of limitations. Previous studies used mostly cross-sectional designs without external validation [7], and though evidence from feeding [5] or experimental [8] designs is promising, it has been hampered by challenges such as the different definitions of the Mediterranean diet or interventions used [5,9,10], the targeting of specific populations [5,8] and the use of subgroup analyses or not fully randomised enrolment of participants [5,11]. Overall, the validity and external generalisability of biomarkers of this dietary pattern reported in the literature remains largely unknown. Given these limitations, biomarker-based assessment of the Mediterranean diet has rarely been applied to the associations with disease outcomes [7] and never previously for T2D.

Our objectives were to derive a nutritional biomarker score that could discriminate between the Mediterranean diet intervention and the habitual diet arms of a randomised controlled trial (RCT), the MedLey trial, and to test the association of the biomarker score with incident T2D in a population-based observational study, the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study. Additionally, we aimed to estimate the potential population impact of greater adherence to the Mediterranean diet, as assessed by the biomarker score, and future risk of T2D. We undertook a comparison between the biomarker score and a score based on self-report as previously reported in the EPIC-InterAct [12].

## Methods

### Study designs and populations

The overall study design and participant flows are displayed in [S1 Fig](#). Briefly, we derived a nutritional biomarker score in the MedLey trial as an objective measure of adherence to the Mediterranean diet, and we applied the score in EPIC-InterAct to test its association with incident T2D. We developed 2 protocols for earlier iterations of this research idea as parts of broader statistical analysis plans. Key analytical decisions pertinent to the current analysis were prespecified in these documents ([S1 Protocol](#)).

The MedLey trial is an RCT that tested effects of the Mediterranean diet on cardiovascular risk factors [13] and cognitive function [14] among healthy adults aged  $\geq 65$  years from metropolitan Adelaide, Australia. We randomised 166 participants to either the Mediterranean diet

with maintenance of baseline body weight or continuation of habitual diet for 6 months in 2013 and 2014 and measured circulating carotenoids [15–18] and fatty acids [15,19–22] to assess compliance [23,24]. Circulating carotenoids are biomarkers of dietary carotenoids or intake of fruits and vegetable [25,26]. Fatty acid profiles reflect across intakes of individual fatty acids and their metabolism, and are affected by dietary fat composition, intake of fish and shellfish, dairy products, nuts, and added fats, including olive oil [27–29]. The Mediterranean diet intervention consisted of fortnightly sessions with the study dietitian and provision of key shelf-stable foods amounting to 30% to 35% of estimated energy requirements: virgin olive oil, low-fat Greek yoghurt, unsalted nuts, canned legumes, and canned tuna. Participants in the habitual diet control group received gift vouchers to local food stores [23,24].

We used the MedLey trial to derive a biomarker score of discrimination between the Mediterranean and habitual diet arms based on end-of-study nutritional biomarkers. Among 137 trial completers out of 166 randomised individuals, we excluded participants with missing nutritional biomarker data ( $n = 4$ ) and those with at least 1 biomarker value outside of the 25th percentile minus 3 times the interquartile range (IQR) or the 75th percentile plus 3 times the IQR ( $n = 5$ ). The analytical sample ( $n = 128$ ) included 67 participants in the Mediterranean diet group and 61 in the habitual diet arm (S1 Fig).

EPIC-InterAct Study is a case-cohort study of T2D nested within the EPIC study in 8 European countries (Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden, and the United Kingdom) [30]. Baseline data collection took place during 1991 to 1998. We ascertained and verified 12,403 individuals with incident T2D from a cohort of 340,234 participants with stored blood samples in the EPIC study. Incident T2D cases were ascertained from a combination of sources, including self-report, primary and secondary care registers, drug registers, hospital admissions, and mortality data, as described in detail previously [30]. From the cohort of 340,234 participants, a centre-stratified subcohort was assembled by randomly selecting 16,835 individuals. A total of 16,154 participants remained in the subcohort after exclusions ( $n = 548$  with prevalent diabetes;  $n = 133$  with uncertain diabetes status). As a result, a case cohort was established ( $n = 27,779$ , including 12,403 incident T2D cases; S1 Fig) [30].

For the current analysis, we excluded participants with missing biomarkers required to calculate the biomarker score ( $n = 5,577$ ), leaving 22,202 participants, with 9,453 participants who developed incident T2D and 13,313 subcohort participants (S1 Fig) followed over an average of 9.7 years. Excluded participants were similar to those included in the analytical sample in terms of the mean baseline age (53.0 versus 51.6 years), BMI (26.3 versus 26.1 kg/m<sup>2</sup>), and the proportion of women (59.0% versus 62.8%) based on subcohort distributions.

All participants provided written informed consent and studies were approved by local ethics committees. The MedLey trial was prospectively registered in the Australian New Zealand Clinical Trials Registry (ACTRN12613000602729). This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist) and Consolidated Standards of Reporting Trials (CONSORT) statement (S2 Checklist).

**Nutritional and metabolic biomarkers.** In the MedLey trial, venous blood samples were taken at baseline, 3 and 6 months post randomisation after 8 h of fasting, centrifuged and stored at  $-80^{\circ}\text{C}$ . High-performance liquid chromatography (HPLC) with photo-diode array detection was used to assay carotenoids [31]. Individual fatty acids were assayed in erythrocyte membranes via direct transesterification as weight% of all the fatty acids measured, followed by gas chromatographic analysis at the Waite Lipid Analysis Service (Adelaide, Australia) [32]. Plasma total cholesterol (TC) was measured using a Siemens ADVIA chemistry analyser at SA Pathology (Adelaide, Australia). Laboratory staff were blinded to randomised intervention allocation.

In EPIC-InterAct, venous blood samples were collected at baseline. Plasma samples were stored in liquid nitrogen (up to  $-196^{\circ}\text{C}$ ). HPLC with ultraviolet light detection was used to measure carotenoids [33,34]. Individual plasma phospholipid fatty acids were assayed as mol% of all fatty acids using automated, high-throughput gas chromatography at the Medical Research Council Human Nutrition Research (Cambridge, United Kingdom) [35,36]. Serum TC was measured at the Stichting Ingenhousz Laboratory (Etten-Leur, the Netherlands) using Roche Hitachi Modular P. Haemoglobin A1c was measured in the erythrocyte fraction using the Tosoh-G8 analyser (Tosoh Bioscience, Japan). Laboratory staff were blinded to case status of participants, and samples were processed in a random order.

Five carotenoid variables were measured in both the MedLey trial and EPIC-InterAct:  $\alpha$ -carotene,  $\beta$ -carotene,  $\beta$ -cryptoxanthin, lutein, and sum of lutein and zeaxanthin. For fatty acids measured in the MedLey trial, units were converted from weight% to mol% to harmonise the data with assays of fatty acids in the EPIC-InterAct. After exclusion of fatty acids with mean concentrations  $<0.05$  mol% of total fatty acids measured, 24 fatty acids overlapped between the MedLey trial and EPIC-InterAct.

**Measurement of covariates and self-reported diet.** In the MedLey trial, questionnaires and physical examination were used to collect data on baseline characteristics. Self-reported diet was measured with 3-day weighed food diaries. Intakes of energy and ethanol were estimated using a local nutrient database [24].

In the EPIC study, questionnaires and physical examination were used at baseline to collect standardised information on covariates, including sociodemographic, medical and health behavioural factors, and anthropometry. Weight, height, and waist circumference were measured at baseline in all EPIC centres, except for Umea, Sweden, where waist circumference was not measured ( $n = 1,845$ ) [30]. Subgroups of participants from France and the Oxford (UK) centre had self-reported anthropometry. Physical activity was assessed using a validated questionnaire [37]. Self-reported diet was measured using country-specific, validated food frequency questionnaires or diet histories. Estimation of intake of foods, energy, and nutrients was harmonised across the EPIC cohorts [38,39]. Information on family history of T2D was not collected in Italy, Spain, and Oxford and Heidelberg centres. Information on current use of vitamin or mineral supplements was not collected in Heidelberg. Covariates had  $<30\%$  missing data within countries except for Germany with 45% of missing data for vitamin/mineral supplement use and family history of T2D. The prevalence of missing information for all countries combined was the highest for family history of T2D (22%), and otherwise up to 9% (dietary supplements), with several covariates having complete data for all participants.

As a measure of self-reported adherence to the Mediterranean diet, we used a score that EPIC-InterAct previously derived (S1 Text) and reported an association with lower T2D incidence [12].

## Statistical analysis

Stata 16.1 and R 4.0.2 were used for statistical analysis.

**Derivation of the biomarker score.** We imputed values of fatty acids below the limit of detection using quantile regression imputation [40]. In the MedLey trial, values were imputed for 5 out of the 24 fatty acids and the proportion of missingness was the highest for C17:1 at 21% and otherwise  $<13\%$ . In EPIC-InterAct, values were imputed for 16 fatty acids, and the corresponding proportions of missingness were 12% (also for C17:1) and  $<6\%$ , respectively. Fatty acids were re-scaled to sum up to 100% within the sets of fatty acids overlapping between the MedLey trial and EPIC-InterAct. Concentrations of circulating carotenoids (ng/mL) were

adjusted for TC using the residual method in order to account for their correlations with dietary carotenoids [41].

We used logistic elastic net regression to derive the biomarker score in MedLeY trial [42,43]. Natural-log-transformed nutritional biomarkers measured at 6 months were used to predict the binary randomised assignment to the Mediterranean or habitual diet groups. We repeated the elastic net regression with random cross-validation 1,000 times to stabilise the variable selection and included in the final model the predictors with selection rate  $\geq 90\%$  [43]. Ridge regression was used to calculate penalised coefficients of the final model [44]. We selected the predictors from 5 carotenoid and 24 fatty acid variables and 406 pairwise interaction terms between them. The biomarker score was calculated as a linear prediction from the ridge regression model. Discriminatory performance was assessed by calculating 5-fold cross-validated C-statistic. The associated 95% confidence interval (CI) was estimated based on the Hanley and McNeil variance formula [45]. Additional details on derivation of the biomarker score are provided in the Supporting information (S1 Text).

**Associations of the biomarker score with incident T2D.** In EPIC-InterAct, individual nutritional biomarkers were Winsorised at 4 standard deviations (SDs) below or above the subcohort means and were then used to calculate the biomarker score with the scoring algorithm developed as described above. The biomarker score was standardised using the means and SD and categorised into quintiles based on the distribution in the subcohort. We performed Prentice-weighted Cox regression analysis with a robust variance estimator to estimate hazard ratios (HRs) for the association between the biomarker score and incident T2D [46]. Country-specific HRs were estimated and pooled using random-effects meta-analysis, followed by calculation of the 95% confidence and prediction intervals [47]. Restricted cubic splines with 5 knots were used to assess potential nonlinearity of the association between the standardised biomarker score and T2D incidence. Country-specific estimates of the spline parameters were pooled with multivariate random-effects meta-analysis [48].

The multivariable-adjusted model included the following covariates: age (as the underlying timescale), sex, recruitment centre, prevalent comorbidity (cancer, cardiovascular disease, hypertension, and hyperlipidaemia), family history of T2D, smoking status (never, former, and current smoker), physical activity index (inactive, moderately inactive, moderately active, and active), seasonality (sine and cosine function of the day of the year of blood draw), fasting status ( $<3$ , 3–6,  $>6$  h), current use of vitamin or mineral supplements, marital status (single, married or cohabiting, divorced or separated, and widowed), educational attainment (none, primary school, technical or professional school, secondary school, and post-secondary school education), current employment, and in women, menopausal status (pre-, peri-, postmenopausal, and bilateral oophorectomy) and current hormone replacement therapy use. A further model was fitted with adjustment for adiposity (BMI and waist circumference as continuous variables; main analytical model). Additional models explored the effects of adjustment for biomarkers constituting the biomarker score. Continuous covariates were Winsorised at 4 SDs below or above the subcohort means. For comparison with the biomarker-based assessment, we estimated the HR for the association with incident T2D of the standardised score of self-reported Mediterranean diet using the main analytical model.

We examined multiplicative interactions of the biomarker score with the following covariates: age, sex, BMI, seasonality, fasting status, use of dietary supplements, physical activity, and smoking status using the adiposity-adjusted model (excluding waist circumference for interaction by BMI) and variable specifications as outlined above. Missing covariate data were imputed by multiple imputation using chained equations in 10 datasets [49], accounting for exposures (biomarker score, nutritional biomarkers), the outcome, model covariates, interaction terms, and country-specific case-cohort design [50]. We also performed a complete-case analysis.



To assess the potential public health impact of a feasible shift in the average population adherence to the Mediterranean diet, we modelled the population attributable fraction (PAF) [51] if the value of the biomarker score for each individual in the study population were to increase by 10 percentiles, assuming a causal relationship. The PAF was estimated in the EPIC-InterAct subcohort separately in each country in the adiposity-adjusted multivariable model, and then combined across countries using random-effects meta-analysis [47]. We used country-specific inverse-probability weights to account for the case-cohort design [52,53]. To facilitate interpretation of the PAF by comparison with an established risk factor, we estimated this measure for a 10 percentile lower BMI after removing from the multivariable model the biomarker score, waist circumference, and physical activity.

**Sensitivity analyses.** We performed several sensitivity analyses to assess the robustness of the main findings. We repeated the derivation and assessment of discriminatory performance of the biomarker score in the MedLey trial with several alternative analytical decisions in the elastic net regression (S1 Text), followed by longitudinal analysis in EPIC-InterAct for each alternative score. Using the primary biomarker score in EPIC-InterAct, time-varying effects were assessed by splitting follow-up time at 7 years and performing stratified analysis. Potential reverse causation bias was evaluated by separately (i) excluding the first 2 years of follow-up; (ii) excluding participants with prevalent major disease conditions (cancer, myocardial infarction, or stroke); and (iii) excluding participants with baseline haemoglobin A1c concentrations  $\geq 6.5\%$  (48 mmol/mol).

**Analyses conducted in response to peer review comments.** We performed a graphical assessment of calibration of the biomarker score model for prediction of randomised assignment in the MedLey trial [54,55]. We tested the discriminatory performance of the biomarker score between  $\geq 90$ th percentile versus  $\leq 10$ th percentile of self-reported adherence to the Mediterranean diet (S1 Text). We assessed the influence of use of pharmacological treatments in our analyses by evaluating: (i) distributions of users of medications by MedLey trial arms (chi-squared test); (ii) multiplicative interactions between use of medications and the biomarker score in logistic regression models for prediction of randomised assignment; (iii) re-derivation of the biomarker score with adjustment of the coefficients for use of medications in the MedLey trial and its impact on the association between the score and incidence of T2D in EPIC-InterAct; and (iv) additional adjustments of the main analytical model in EPIC-InterAct for use of medications in subsets of participants with information available on these covariates.

## Patient and public involvement

The MedLey trial intervention was piloted in a group of volunteers that led to minor adjustments in its design and delivery [56]. Patients or public were otherwise not involved in study design.

## Results

Compared to the MedLey trial participants, the EPIC-InterAct subcohort members were younger (mean age 52 years, EPIC-InterAct, versus 71 years, MedLey trial), had lower tertiary educational attainment (20% versus 53%), were less likely to have a family history of T2D (18% versus 30%), and had higher prevalence of hypertension (36% versus 19%) and hyperlipidaemia (38% versus 17%). The study populations were similar with regards to dietary and cardiometabolic phenotypes (Table 1). The Mediterranean diet intervention in the MedLey trial resulted in increases in the concentrations of  $\beta$ -carotene, lycopene, C22:6-n3 (docosahexaenoic), C20:2-n6 (eicosadienoic), and long- and very-long chain monounsaturated fatty acids, and decreases in the concentrations of C22:5-n6 (osbond), C17:1 (heptadecenoic) and several

**Table 1. Baseline characteristics of participants of the MedLey randomised partial-feeding controlled trial of the Mediterranean diet and the EPIC-InterAct case-cohort study\*.**

	MedLey trial	EPIC-InterAct	
		Subcohort	Cases of T2D
Number of participants	128	13,313	9,453
Age, years	71 (5)	52 (9)	55 (8)
Women, %	54	63	50
Postmenopausal, % <sup>†</sup>	100	44	60
Hormone therapy use, % <sup>†</sup>	5	14	14
Current smokers, %	0	26	28
Moderately active or active, %	- <sup>‡</sup>	43	38
Tertiary education, %	56	20	13
Currently employed, %	21	67	58
Family history of T2D, %	31	18	34
Disease history, %			
Hypertension	36	19	39
Hyperlipidaemia	38	17	27
Cardiovascular disease	5.0	1.9	4.0
Cancer	-	2.4	2.5
Mediterranean diet score, 0–18 points	9.7 (2.6)	8.8 (3.1)	8.5 (3.2)
Score components, g/1,000 kcal			
Vegetable	83 (67)	94 (64)	92 (66)
Legumes	8.2 (17.4)	9.2 (13.2)	9.4 (14.3)
Fruits and nuts	136 (75)	123 (99)	119 (102)
Grains and grain products	72 (39)	104 (41)	103 (43)
Fish and shellfish	24 (26)	18 (16)	20 (18)
Meat and meat products	35 (32)	52 (24)	58 (25)
Milk and milk products	130 (95)	163 (114)	160 (122)
Olive oil	2.0 (3.4)	4.3 (6.3)	4.0 (6.3)
Ethanol	4.6 (5.0)	6.0 (7.7)	6.5 (8.7)
Dietary supplement use, %	66	39	41
Body mass index, kg/m <sup>2</sup>	26.5 (3.5)	26.1 (4.2)	29.9 (4.7)
Waist circumference, cm	90 (13)	87 (13)	98 (12)
Haemoglobin A1c, mmol/mol	-	35.9 (4.9)	43.1 (11.1)
≥6.5% (48 mmol/mol), %	-	1	17
Total cholesterol, mmol/L	5.2 (0.9)	5.9 (1.1)	6.1 (1.2)
HDL cholesterol, mmol/L	1.65 (0.44)	1.50 (0.42)	1.25 (0.37)
Triglycerides, mmol/L	1.13 (0.45)	1.33 (0.91)	1.98 (1.41)

\*Values are means (standard deviations) or percentages. The EPIC-InterAct subcohort participants and incident cases of T2D were independently sampled from the underlying EPIC cohort. As a feature of the case-cohort design, 564 incident cases included in the analysis were simultaneously subcohort participants.

<sup>†</sup>Calculated in women.

<sup>‡</sup>Data unavailable in the MedLey trial.

EPIC, European Prospective Investigation into Cancer and Nutrition; HDL, high density lipoprotein; T2D, type 2 diabetes.

<https://doi.org/10.1371/journal.pmed.1004221.t001>

saturated fatty acids (S2 Fig). The effect sizes relative to the habitual diet control group ranged from  $-0.67$  SD for C14:0 (myristic) to  $0.76$  SD for C20:1 (gondoic acid). Blood levels of these biomarkers varied between the MedLey trial and EPIC-InterAct. For example, comparing median concentrations in the MedLey trial habitual diet group and ranges of medians by country in the EPIC-InterAct subcohort, we observed differences for  $\beta$ -carotene (726 and 144

to 419 ng/mL), lycopene (110 and 172 to 348 ng/mL), C24:1 (1.22 and 0.32 to 0.37%mol), and C24:0 (1.07 and 0.20 to 0.26%mol) fatty acids (S1 Table).

### Derivation of the biomarker score

The biomarker score consisted of a linear combination of 23 biomarkers in total (S2 Table). The score distinguished 2 arms of the Mediterranean and habitual diet groups with C-statistic = 0.88 (95% CI: 0.82 to 0.94) and moderate calibration (S3 Fig). We did not find any evidence of interaction between medication use and the biomarker score (S3 Table). After standardisation of the score in the MedLey trial, mean end-of-trial score values were higher by 1.81 (95% CI: 1.45 to 2.18) points in the Mediterranean than the habitual diet group. In EPI-C-InterAct, baseline medians of the biomarker score standardised using the overall subcohort distribution ranged between countries from  $-0.35$  in Spain to  $0.71$  SD in Sweden (Fig 1 and S4 Table). The C-statistic values for discrimination between extreme categories of self-reported Mediterranean diet by the biomarker score were 0.63 (95% CI: 0.38 to 0.87;  $n = 42$ ) in the MedLey trial baseline sample and 0.59 (95% CI: 0.58 to 0.61;  $n = 4,298$ ) in the EPIC-InterAct subcohort, with country-specific values ranging from 0.54 in Germany to 0.68 in Spain.


### The association of the biomarker score with incident T2D

The biomarker score of the Mediterranean diet was inversely associated with incident T2D (Table 2). In the adiposity-adjusted multivariable model, the HR (95% CI) for the top fifth of the biomarker score compared to the bottom fifth was 0.38 (0.30 to 0.50) ( $p$  trend = 0.012). The HR (95% CI) per 1 SD was 0.71 (0.65 to 0.77) with inverse associations in all countries, moderate heterogeneity between country-specific estimates ( $I^2 = 67\%$ ) and a 95% prediction interval of 0.55 to 0.91 (Fig 2). We found weak evidence of departure from linearity ( $p$  nonlinearity = 0.044, Fig 2) where the inverse association levelled off in approximately the upper fifth of the distributions of the score. The association remained statistically significant after additional adjustments for individual and all biomarkers or interaction terms included in the score (S5 Table). The estimated PAF (95% CI) was 11% (7% to 14%), indicating that the incidence of T2D could be reduced by 11% if the biomarker score were increased by 10 percentiles, assuming a causal relationship. For comparison, the estimated PAF (95% CI) for a 10 percentile lower BMI was 28% (20% to 35%).

The main result was robust to multiple sensitivity analyses which explored the effects of time of follow-up, reverse causation, alternative analytical decisions at the stage of derivation of the biomarker score, and additional adjustment for use of medications (S5 Table). Among the potential effect modifiers, we found evidence of interaction of the biomarker score with age and the use of dietary supplements (S6 Table). The HR (95% CI) per 1 SD of the biomarker score was 0.76 (0.69 to 0.84) in supplement users and 0.69 (0.62 to 0.75) in non-users. The stratum-specific estimates by age at baseline <45, 45–60, and >60 years were 0.54 (0.42 to 0.69), 0.74 (0.69 to 0.80), and 0.74 (0.67 to 0.82), respectively. The results from complete-case analysis were similar to the multiple imputation estimates (S6 Table). The HR (95% CI) per 1 SD of the score of self-reported Mediterranean diet was 0.90 (0.86 to 0.95).

### Discussion

In the current research, we combined information from experimental and observational studies to investigate the association between a composite biomarker score of adherence to the Mediterranean diet and incident T2D. The key findings were that a biomarker score derived within the MedLey RCT had a high discriminatory performance between the Mediterranean and habitual diet arms, and that when this biomarker score was applied to the pan-European



**Fig 1. Nutritional biomarker score of the Mediterranean diet: study-specific distribution by the MedLey trial arms post-intervention and the EPIC-InterAct subcohort by country at baseline.** The biomarker score was derived as a discriminatory model between the Mediterranean and habitual diet in the MedLey randomised partial-feeding controlled trial. Circulating carotenoids and fatty acids were used to calculate the score as linear predictions from the discriminatory model. The score was standardised separately within the MedLey trial and the EPIC-InterAct subcohort. Boxes denote the IQR and medians inside; and whiskers, values up to 1.5 IQR outside of these percentiles. EPIC, European Prospective Investigation into Cancer and Nutrition; IQR, interquartile range; UK, United Kingdom.

<https://doi.org/10.1371/journal.pmed.1004221.g001>

EPIC-InterAct Study, there was an inverse association with incident T2D. The 95% prediction interval for this association did not include the null, suggesting that our finding would be expected to be replicated in similar populations [57]. The strength of the association was greater in magnitude than that between the self-reported Mediterranean diet and T2D. Moreover, higher adherence to the Mediterranean diet (as reflected by a 10-percentile higher value of the biomarker score) could reduce the incidence of T2D by 11%, assuming a causal relationship which cannot be confirmed by the present study.

### Comparison with previous studies

Attempts to derive biomarkers of the Mediterranean diet and other dietary patterns have previously been largely confined to metabolomic profiling using cross-sectional designs [7,58]. In a subgroup analysis in one of the centres of the PREDIMED trial, urinary metabolomic profiles at 1 or 3 years post-randomisation were able to correctly classify 93%, 85%, and 68% of participants to their respective intervention arms of the Mediterranean diet with either olive oil or nuts and the control lower fat diet [8]. Only 2 previous studies considered scores comprised of nutritional biomarkers [5,59], one of which used a hypothesis-free approach that was likely

**Table 2. Associations between the nutritional biomarker score of the Mediterranean diet\* with incidence of T2D in the European Prospective Investigation into Cancer and Nutrition-InterAct (*n* = 22,202).**

Model	Quintiles					P <sub>trend</sub> <sup>‡</sup>	Per 1 SD	I <sup>2</sup> , % (95% CI)
	Q1	Q2	Q3	Q4	Q5			
Number of cases	2,779	1,954	1,698	1,508	1,514			
IR per 100,000 person-years	572	407	286	252	268			
Pooled HRs (95% CIs) <sup>†</sup>								
Age, sex, and centre adjusted	1.0 (Ref.)	0.64 (0.58–0.69)	0.49 (0.44–0.54)	0.40 (0.34–0.47)	0.34 (0.28–0.41)	<0.001	0.65 (0.61–0.69)	69 (39–85)
Multivariable adjusted <sup>†</sup>	1.0 (Ref.)	0.66 (0.60–0.73)	0.53 (0.46–0.60)	0.43 (0.37–0.49)	0.36 (0.29–0.45)	<0.001	0.67 (0.62–0.72)	67 (33–84)
+adiposity	1.0 (Ref.)	0.69 (0.62–0.77)	0.59 (0.52–0.67)	0.48 (0.40–0.58)	0.38 (0.30–0.50)	0.012	0.71 (0.65–0.77)	67 (30–84)

\*The biomarker score was derived as a discriminatory model between the Mediterranean and habitual diet in the MedLey randomised partial-feeding controlled trial. Circulating carotenoids and fatty acids were used to calculate the score as linear predictions from the discriminatory model.

<sup>†</sup>Hazard ratios were pooled from country-specific estimates. Multivariable adjusted model included the following covariates: age (as timescale), sex, recruitment centre, prevalent cancer, cardiovascular disease, hypertension and hyperlipidaemia, familial history of T2D, smoking status (never, former, current smoker), physical activity index (inactive, moderately inactive, moderately active, active), seasonality (sine and cosine function of the day of the year), fasting status (<3, 3–6, >6 h), current use of vitamin or mineral supplements, marital status (single, married or cohabiting, divorced or separated, widowed), educational attainment (none, primary school, technical or professional school, secondary school, post-secondary school education), current employment, and in women, menopausal status (pre-, peri-, postmenopausal, bilateral oophorectomy), current hormone replacement therapy use. Adjustment for adiposity included body mass index and waist circumference.

<sup>‡</sup>Generalised least-squares trend estimation method was used to calculate *p*-values for a linear trend over an ordinal variable of median biomarker scores of the 5 quintile groups.


CI, confidence interval; HR, hazard ratio; IR, incidence rate; SD, standard deviation; T2D, type 2 diabetes.

<https://doi.org/10.1371/journal.pmed.1004221.t002>


prone to confounding by non-dietary regulation of nutritional biomarkers [59]. The second study used a novel feeding design of habitual diets and performed data-driven variable selection from a wider range of nutritional biomarkers than available in our investigation: serum phospholipid fatty acids, carotenoids, tocopherols, retinol, B vitamins, and 24-h urinary nitrogen, sodium, potassium, and energy expenditure estimated from the doubly labelled water technique [5]. The study derived a biomarker score that was well correlated with quantified habitual adherence to the Mediterranean diet ( $r_{\text{cross-validated}} = 0.60$ ). It included 2 circulating carotenoids and 7 fatty acids that constituted 81% of the prediction performance, as well as urinary potassium and energy expenditure [5]. This finding corroborates our results and the hypothesis that combinations of nutritional biomarkers, and in particular circulating carotenoids and fatty acids, can be used to objectively assess adherence to the Mediterranean diet [15–22]. Importantly, it also highlights the remaining biomarkers not selected into the score as potentially having limited value for assessment of the Mediterranean dietary pattern, which is supported by interventional evidence for some of these analytes, e.g., for tocopherols [16]. Studies on other dietary patterns likewise suggest utility of combinations of carotenoids and fatty acids for their objective assessment [5,60–62]. It is prudent for future research on biomarker scores of the Mediterranean diet to evaluate further groups of nutritional biomarkers in a data-driven manner. For example, biomarkers of polyphenols are promising [21,63], however, the evidence is limited and their utility has so far not been assessed in the context of multivariate modelling.

Our work on derivation of the nutritional biomarker score of the Mediterranean diet adds to the previous literature by incorporating the strength of an RCT. Owing to the RCT design of the MedLey trial, we were able to minimise confounding by non-nutritional factors, and thus derive a biomarker score with potentially improved generalisability to external populations. A further novelty of our work is the application of the experimentally derived score to prospective associations between dietary patterns at large and disease outcomes. To our

### Country-specific and pooled associations



### Non-linear association



**Fig 2. Association between the nutritional biomarker score of the Mediterranean diet and incidence of T2D in the EPIC-InterAct case-cohort study ( $n = 22,202$ ).** The biomarker score was derived as a discriminatory model between the Mediterranean and habitual diet in the MedLey randomised partial-feeding controlled trial. Circulating carotenoids and fatty acids were used to calculate the score as linear predictions from the discriminatory model. Associations were assessed with the Prentice-weighted Cox regression and pooled by random-effects meta-analysis. Top: The diamond and error bars of the pooled estimate represent the 95% confidence and prediction intervals. Bottom: Restricted cubic splines with 5 knots were

used to model the nonlinear association. The *p*-value for the test of nonlinearity was 0.044. Black solid line represents point estimates of HRs and purple area denotes the 95% CI. The 10th percentile of the subcohort distribution was used as reference. Associations were adjusted for: age (as timescale), sex, recruitment centre, prevalent cancer, cardiovascular disease, hypertension and hyperlipidaemia, familial history of type 2 diabetes, smoking status (never, former, current smoker), physical activity index (inactive, moderately inactive, moderately active, active), seasonality (sine and cosine function of the day of the year), fasting status (<3, 3–6, >6 h), current use of vitamin or mineral supplements, marital status (single, married or cohabiting, divorced or separated, widowed), educational attainment (none, primary school, technical or professional school, secondary school, post-secondary school education), current employment, body mass index and waist circumference, and in women, menopausal status (pre-, peri-, postmenopausal, bilateral oophorectomy) and current hormone replacement therapy use. CI, confidence interval; HR, hazard ratio; SD, standard deviation; T2D, type 2 diabetes.

<https://doi.org/10.1371/journal.pmed.1004221.g002>

knowledge, the only other example of derivation and application of a putative biomarker of the Mediterranean diet to associations with disease endpoints was a metabolomics-based analysis in the Spanish PREDIMED study and prospective cohorts in the USA. Similar to our analysis, it observed inverse associations for cardiovascular disease using the metabolite score observationally derived in PREDIMED across all cohorts (HR range per 1 SD: 0.71 to 0.86) and weaker or null associations when using the self-reported Mediterranean diet [64]. Of note, these results also provide evidence in support of transferability of objective exposure assessment measures across populations for epidemiological investigations. This is particularly pertinent to the current manuscript in which we were unable to test the association of the biomarker score with incidence of T2D in the target population of the MedLey trial.

For incident T2D, the PREDIMED trial reported a 30% risk reduction in the Mediterranean diet intervention arms relative to the control lower fat diet group (273 incident cases in 3,541 participants) [65]. The CORDIOPREV trial reported a statistically nonsignificantly higher incidence of T2D in the Mediterranean diet arm compared to the lower fat control group (HR 1.35; 95% CI: 0.91 to 2.01; 107 cases in 462 participants) [66]. This finding from a secondary CVD prevention trial among participants predominantly with pre-diabetes (85% prevalence) is of lower relevance to prevention of T2D in the general population than that of the PREDIMED trial. Beyond moderating effects of population characteristics, the result of the CORDIOPREV trial may have been driven towards favouring the lower fat diet by a small mean weight loss over 5 years (−1.14 kg) compared to a small average weight gain in the Mediterranean diet arm (+0.78 kg) [66]. Inverse associations between the self-reported Mediterranean diet and incident T2D in middle-aged adults have previously been reported in EPIC-InterAct [12] and other prospective cohorts [2]. The largest reduction in the incidence between extreme categories of the self-reported adherence to the Mediterranean diet was 25% (top versus bottom fifth) [67], which is a substantially smaller effect size than the 62% observed in the current study using the biomarker score.

## Strengths and limitations

The major strength of the current research was the use of a novel analytical approach that combined the derivation of an objective measure of the Mediterranean diet in a partial-feeding study (the MedLey RCT) and its application in a large observational study (the EPIC-InterAct Study). The RCT compared the effects of this dietary pattern (without weight loss) with continuation of habitual diet on nutritional biomarkers. Such an experimental design allowed us to derive a biomarker score of the Mediterranean diet in a manner that was free from influences of other dietary and non-dietary factors, while using a control group suitable for application of the score to study participants in an observational setting in Western countries. We used a set of biomarkers that reflect dietary exposures over the past weeks or months [68] that is a desirable timeframe for assessment of habitual diet for epidemiological applications. Our analysis was based on the largest study to date of nutritional biomarkers and T2D, including over 9,000

incident cases. Among other strengths, our observational analyses adjusted for a comprehensive range of potential confounding factors and included several sensitivity analyses, compared the main results against the Mediterranean diet assessed by self-report, and modelled the population impact of greater adherence to the Mediterranean diet on future T2D risk.

Our research had several limitations. The intervention in the MedLey trial was administered at one level of intensity. This allowed for modelling of the Mediterranean diet only as a binary variable and precluded objective evaluation of the dose-response relationship between the adherence to this dietary pattern and the biomarker score [69]. Second, the MedLey trial was a partial-feeding RCT that may have resulted in lower adherence to the dietary components not provided (e.g., fruits and vegetables) than the food items provided as part of the Mediterranean diet intervention. Third, we used a combination of candidate biomarkers of intake, concentration, and function that are not only affected by dietary intakes, but also bio-availability, endogenous synthesis, genetic variation, homeostatic control, and nutrient metabolism [27,70,71]. Thus, changes in nutritional biomarkers in the MedLey trial may have represented a metabolic response to a healthy diet, rather than a specific biomarker profile indicative of adherence to the Mediterranean diet. Fourth, we were unable to assess whether participants in the intervention group reached equilibrium in concentrations of nutritional biomarkers and values of the biomarker score. Fifth, the trial experienced a moderate degree of drop-outs between the randomisation and the end-of-trial assessment (20% in each arm, including missing biomarker data). Both the unknown equilibrium status and the loss to follow-up [72] may have biased the derivation of the RCT score and evaluation of its performance as a classifier. The biomarker score had limited utility in discriminating between extreme categories of self-reported adherence to the Mediterranean diet; however, the measurement error due to subjective reporting and potentially insufficient construct validity of the self-reported Mediterranean diet score may have meant the C-statistics were underestimated. Sensitivity and specificity of the biomarker score, as well as external validity, remain unknown at present and require evaluation of the score in external trials of interventions with the Mediterranean diet and other dietary patterns. We also note that the MedLey trial used canned fish and legumes as a pragmatic, nontraditional approach to implementation of these components of the Mediterranean diet; however, we would not expect this method of preservation to have a materially differential effect on the biomarkers used compared to cooked fresh fish and beans cooked from dry.

Limitations in the observational research in EPIC-InterAct included residual confounding as a potential source of bias with an overall unclear direction and magnitude. It was unlikely to fully account for the inverse association given its large effect size and the effect sizes of risk factors for T2D previously reported in the literature [73,74]. However, the above mentioned potentially limited specificity may have contributed to positive residual confounding. There may have been degradation of the nutritional biomarkers despite the storage in liquid nitrogen, but we would not expect any bias in the relative risk estimate assuming the degradation rates were non-differential by the incident case status or biomarker level. The random measurement error in the nutritional biomarkers would be expected to bias the association towards the null when considered in isolation from other sources of error, but the context of multivariable statistical modelling precludes any inference on the direction of the potential bias [4]. The differential misclassification in the ascertainment of the outcome also may have biased the results in an unknown direction. We can speculate that higher adherence to the Mediterranean diet may have been associated with greater health-consciousness and health-care-seeking behaviours, higher likelihood of T2D diagnosis, and an underestimation of the inverse association. We standardised the measures of the Mediterranean diet to improve interpretability of the results for the biomarker score over its original scale and to allow for a



comparison of the effect size with that of the self-reported Mediterranean diet. This approach conditioned the effect sizes on the underlying distributions of the exposure variables in EPIC-InterAct which may have limited our quantitative and comparative interpretation [75]. Similarly, our modelling of the PAF was limited by using a relative scale of the biomarker score to quantify its potential impact on population-level prevention of T2D. Public health relevance of this result was further constrained by the fact that the current evidence-base does not enable a direct interpretation of how to achieve the 10-percentile change in the score. Our analysis was not adjusted for use of medications due to incomplete availability of data on these covariates across recruitment centres (<30% participants). However, sensitivity analyses adjusted for use of medications in subsets of study participants showed no appreciable differences compared with the primary results, reducing the potential for residual confounding by medication use. The use of dietary supplements was available as a binary variable that allowed only for a crude assessment of effect modification. Finally, reliability of the externally derived biomarker score applied to biomarker assays used in EPIC-InterAct remains unknown.

### Implications of this research

The analysis of dietary patterns aims to evaluate the cumulative impact of dietary exposures on disease risk to inform development of dietary guidelines [1]. High-quality evidence on dietary patterns and the primary prevention of T2D is lacking, partly because of limitations of dietary assessment methods [3]. Self-reported tools have been used almost exclusively in the published studies on this topic [3,76]. We have developed a method of objective assessment of the Mediterranean diet via nutritional biomarkers in order to investigate the association of this dietary pattern and T2D. Our approach of using objective biomarkers yielded substantially greater magnitude and stronger inverse associations than for the Mediterranean diet assessed with subjective methods, also consequently addressing the limitation of small effect sizes often observed in nutritional epidemiology [77]. Our modelling indicates that a modest, 10-percentile increase in the objectively assessed Mediterranean diet could potentially avert 11% of new T2D cases. In comparative analysis, this effect size was approximately 40% of the estimated effect of decreasing mean BMI by 10 percentiles as an example of a well-established, causal risk factor for T2D with a large effect size [74]. Of note, the inverse associations of the biomarker score with T2D in the current study were independent from measured adiposity, with no evidence of effect modification by BMI. Therefore, our finding suggests that a sizeable decrease in the incidence of T2D could potentially be achieved through improved adherence to the Mediterranean diet even in the absence of modification of body weight and across the spectrum of adiposity in the population.

Our integrative approach of using a trial and an observational study with nutritional biomarkers strengthens the evidence for the utility of biomarkers in research on dietary patterns. Further investigations are warranted for a broader use of biomarkers to monitor dietary adherence in research, clinical settings, and potentially of preventive interventions in the real world. Our primary finding was consistent with interventional evidence from a Mediterranean (Spanish) population [65], and it lends itself to consideration for developing dietary guidelines, public health policy, and personalised dietary advice.

### Conclusions

The findings of the current study have demonstrated the utility of combining circulating carotenoids and fatty acids as a composite biomarker of the Mediterranean diet. The inverse association between a biomarker score of this dietary pattern and T2D was approximately 3-fold larger than for adherence to the Mediterranean diet estimated from dietary self-report, thus

raising the possibility that adherence to the Mediterranean diet is likely to be more beneficial for the primary prevention of T2D than previously estimated from observational dietary studies. These results add to the evidence in favour of adopting a Mediterranean-type diet in Western European adults for the prevention of T2D.

## Supporting information

**S1 Checklist. STROBE Statement—Checklist of items that should be included in reports of cohort studies.**

(DOCX)

**S2 Checklist. CONSORT 2010 checklist of information to include when reporting a randomised trial.**

(DOCX)

**S1 Text. Supplementary methods.**

(DOCX)

**S1 Table. Medians (25th, 75th percentile) of circulating carotenoids and fatty acids: the MedLey trial post-intervention and the EPIC-InterAct subcohort at baseline.** Abbreviations: Hab, habitual; Med, Mediterranean.

(DOCX)

**S2 Table. Biomarker scores of discrimination between the Mediterranean and habitual diet in the MedLey trial.** Abbreviations: mol%, molar percent; RCT, randomised controlled trial; SD, standard deviation; wt%, weight percent;  $\beta$ -crypt.,  $\beta$ -cryptoxanthin.

(DOCX)

**S3 Table. Percentages (numbers) of users of medications in the MedLey trial by randomised assignment at baseline ( $n = 152$ ) and in the biomarker score derivation sample ( $n = 128$ ).**

(DOCX)

**S4 Table. Medians (interquartile ranges) of the nutritional biomarker score of the Mediterranean diet in the MedLey trial post-intervention and in the EPIC-InterAct subcohort.**

Abbreviations: Hab, habitual; Med, Mediterranean;  $n$ , number of participants.

(DOCX)

**S5 Table. Nutritional biomarker score of the Mediterranean diet derived in the MedLey trial and incidence of type 2 diabetes in EPIC-InterAct: sensitivity analyses.** Abbreviations: CI, confidence interval; EPIC, European Prospective Investigation into Cancer and Nutrition; HR, hazard ratio; MI, myocardial infarction; RCT, randomised controlled trial; SD, standard deviation.

(DOCX)

**S6 Table. Nutritional biomarker score of the Mediterranean diet derived in the MedLey trial and incidence of type 2 diabetes in EPIC-InterAct: associations per 1 standard deviation by categories of covariates.** Abbreviations: CI, confidence interval; EPIC, European Prospective Investigation into Cancer and Nutrition; HR, hazard ratio; RCT, randomised controlled trial.

(DOCX)

**S7 Table. The score of self-reported Mediterranean diet.**

(DOCX)

**S1 Fig. Designs of the MedLey trial and the EPIC-InterAct case-cohort study and numbers of participants included in the analysis.**

(DOCX)

**S2 Fig. Differences in standardised means of nutritional biomarkers between the Mediterranean and habitual diet groups in the MedLey trial at 6 months.** Abbreviations: AA, arachidonic acid; ALA,  $\alpha$ -linolenic acid; DGLA, dihomo- $\gamma$ -linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; FAs, fatty acids; LA, linoleic acid. Mixed linear models were used to estimate standardised differences after 6 months of partial-feeding intervention. Standardised values were calculated using baseline means and standard deviations of natural logarithm-transformed values of biomarkers. Horizontal error bars indicate 95% confidence intervals. Between 131–136 participants had non-missing biomarker data at 6 months.

(DOCX)

**S3 Fig. Calibration plots of the nutritional biomarker score for prediction of randomised assignment to 6 months of the Mediterranean diet ( $n = 67$ ) versus continuation of habitual diet ( $n = 61$ ) in the MedLey trial.** Abbreviations: AUC, area under the curve; CITL, calibration-in-the-large; E:O, ratio of expected and observed outcomes.

(DOCX)

**S1 Protocol. Study protocol.**

(DOCX)

## Acknowledgments

We thank all the MedLey trial and EPIC participants and staff for their contribution to the study. The authors acknowledge the MedLey team for their support in the recruitment, data collection, and analysis during the trial. The authors acknowledge the following industry partners for donations of foods for the trial: Cobram Estate; Peanut Company of Australia; The Grains & Legumes Nutrition Council; Simplot Australia Pty. Ltd.; Goodman Fielder Ltd; and The Almond Board of Australia. We thank the technical and functional operational teams of the MRC Epidemiology Unit and laboratory team at VITAS AS, Norway, for the measurements of plasma carotenoids in the EPIC-InterAct study. We thank staff from the EPIC-InterAct and EPIC-CVD Coordinating Centres for carrying out sample preparation and data-handling work, particularly Nicola Kerrison (Data Manager, MRC Epidemiology Unit, Cambridge) and Sarah Spackman (EPIC-CVD Data Manager). We acknowledge Dr. Rosario Tumino as data contributor from the Ragusa EPIC centre.

The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

## Author Contributions

**Conceptualization:** Jakub G. Sobiecki, Fumiaki Imamura, Nita G. Forouhi.

**Data curation:** Albert Koulman, Thomas E. Gundersen.

**Formal analysis:** Jakub G. Sobiecki.

**Funding acquisition:** John Danesh, Adam S. Butterworth, Elio Riboli, Karen J. Murphy, Nicholas J. Wareham, Nita G. Forouhi.

**Investigation:** Jakub G. Sobiecki, Fumiaki Imamura, Courtney R. Davis, Stephen J. Sharp, Albert Koulman, Jonathan M. Hodgson, Marcela Guevara, Matthias B. Schulze, Ju-Sheng

Zheng, Claudia Agnoli, Catalina Bonet, Sandra M. Colorado-Yohar, Guy Fagherazzi, Paul W. Franks, Thomas E. Gundersen, Franziska Jannasch, Rudolf Kaaks, Verena Katzke, Esther Molina-Montes, Peter M. Nilsson, Domenico Palli, Salvatore Panico, Keren Papier, Olov Rolandsson, Carlotta Sacerdote, Anne Tjønneland, Tammy Y. N. Tong, Yvonne T. van der Schouw, John Danesh, Adam S. Butterworth, Elio Riboli, Karen J. Murphy, Nicholas J. Wareham, Nita G. Forouhi.

**Methodology:** Jakub G. Sobiecki, Fumiaki Imamura, Courtney R. Davis, Stephen J. Sharp, Albert Koulman, Jonathan M. Hodgson, Marcela Guevara, Matthias B. Schulze, Ju-Sheng Zheng, Elio Riboli, Karen J. Murphy, Nicholas J. Wareham, Nita G. Forouhi.

**Project administration:** Jakub G. Sobiecki, Elio Riboli, Karen J. Murphy, Nicholas J. Wareham, Nita G. Forouhi.

**Resources:** Albert Koulman, Claudia Agnoli, Catalina Bonet, Sandra M. Colorado-Yohar, Guy Fagherazzi, Paul W. Franks, Thomas E. Gundersen, Franziska Jannasch, Rudolf Kaaks, Verena Katzke, Esther Molina-Montes, Peter M. Nilsson, Domenico Palli, Salvatore Panico, Keren Papier, Olov Rolandsson, Carlotta Sacerdote, Anne Tjønneland, Tammy Y. N. Tong, Yvonne T. van der Schouw, John Danesh, Adam S. Butterworth, Elio Riboli, Karen J. Murphy, Nicholas J. Wareham, Nita G. Forouhi.

**Supervision:** Fumiaki Imamura, Stephen J. Sharp, Nita G. Forouhi.

**Visualization:** Jakub G. Sobiecki.

**Writing – original draft:** Jakub G. Sobiecki.

**Writing – review & editing:** Jakub G. Sobiecki, Fumiaki Imamura, Courtney R. Davis, Stephen J. Sharp, Albert Koulman, Jonathan M. Hodgson, Marcela Guevara, Matthias B. Schulze, Ju-Sheng Zheng, Claudia Agnoli, Catalina Bonet, Sandra M. Colorado-Yohar, Guy Fagherazzi, Paul W. Franks, Thomas E. Gundersen, Franziska Jannasch, Rudolf Kaaks, Verena Katzke, Esther Molina-Montes, Peter M. Nilsson, Domenico Palli, Salvatore Panico, Keren Papier, Olov Rolandsson, Carlotta Sacerdote, Anne Tjønneland, Tammy Y. N. Tong, Yvonne T. van der Schouw, John Danesh, Adam S. Butterworth, Elio Riboli, Karen J. Murphy, Nicholas J. Wareham, Nita G. Forouhi.

## References

1. Schulze MB, Martínez-González MA, Fung TT, Lichtenstein AH, Forouhi NG. Food based dietary patterns and chronic disease prevention. *BMJ*. 2018; 361:k2396. <https://doi.org/10.1136/bmj.k2396> PMID: 29898951
2. Jannasch F, Kröger J, Schulze MB. Dietary Patterns and Type 2 Diabetes: A Systematic Literature Review and Meta-Analysis of Prospective Studies. *J Nutr*. 2017; 147:1174–1182. <https://doi.org/10.3945/jn.116.242552> PMID: 28424256
3. Neuenschwander M, Ballon A, Weber KS, Norat T, Aune D, Schwingshackl L, et al. Role of diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies. *BMJ*. 2019; 366:l2368. <https://doi.org/10.1136/bmj.l2368> PMID: 31270064
4. Bennett DA, Landry D, Little J, Minelli C. Systematic review of statistical approaches to quantify, or correct for, measurement error in a continuous exposure in nutritional epidemiology. *BMC Med Res Methodol*. 2017; 17:1–22. <https://doi.org/10.1186/s12874-017-0421-6> PMID: 28927376
5. Neuhouwer ML, Pettinger M, Lampe JW, Tinker LF, George SM, Reedy J, et al. Novel Application of Nutritional Biomarkers From a Controlled Feeding Study and an Observational Study to Characterization of Dietary Patterns in Postmenopausal Women. *Am J Epidemiol*. 2021; 190:2461–2473. <https://doi.org/10.1093/aje/kwab171> PMID: 34142699
6. Garcia-Aloy M, Rabassa M, Casas-Agustench P, Hidalgo-Liberona N, Llorach R, Andres-Lacueva C. Novel strategies for improving dietary exposure assessment: Multiple-data fusion is a more accurate

- measure than the traditional single-biomarker approach. *Trends Food Sci Technol.* 2017; 69:220–229. <https://doi.org/10.1016/j.tifs.2017.04.013>
7. Kim H, Rebholz CM. Metabolomic Biomarkers of Healthy Dietary Patterns and Cardiovascular Outcomes. *Curr Atheroscler Rep.* 2021; 23:26. <https://doi.org/10.1007/s11883-021-00921-8> PMID: 33782776
  8. Vázquez-Fresno R, Llorach R, Urpi-Sarda M, Lupianez-Barbero A, Estruch R, Corella D, et al. Metabolomic pattern analysis after Mediterranean diet intervention in a nondiabetic population: A 1- and 3-year follow-up in the PREDIMED study. *J Proteome Res.* 2015; 14:531–540. <https://doi.org/10.1021/pr5007894> PMID: 25353684
  9. Appel LJ, Van Horn L. Did the PREDIMED Trial Test a Mediterranean Diet? *N Engl J Med.* 2013; 368:1353–1354. <https://doi.org/10.1056/NEJMe1301582> PMID: 23550674
  10. Hutchins-Wiese HL, Bales CW, Starr KNP. Mediterranean diet scoring systems: understanding the evolution and applications for Mediterranean and non-Mediterranean countries. *Br J Nutr.* 2021;1–22. <https://doi.org/10.1017/S0007114521002476> PMID: 34289917
  11. Estruch R, Ros E, Salas-Salvadó J, Covas M-II, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med.* 2018; 378:e34. <https://doi.org/10.1056/NEJMoa1800389> PMID: 29897866
  12. Romaguera D, Guevara M, Norat T, Langenberg C, Forouhi NG, Sharp S, et al. Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: the InterAct project. *Diabetes Care.* 2011; 34:1913–1918. <https://doi.org/10.2337/dc11-0891> PMID: 21788627
  13. Davis CR, Hodgson JM, Woodman R, Bryan J, Wilson C, Murphy KJ. A Mediterranean diet lowers blood pressure and improves endothelial function: Results from the MedLey randomized intervention trial. *Am J Clin Nutr.* 2017; 105:1305–1313. <https://doi.org/10.3945/ajcn.116.146803> PMID: 28424187
  14. Knight A, Bryan J, Wilson C, Hodgson JM, Davis CR, Murphy KJ. The Mediterranean Diet and Cognitive Function among Healthy Older Adults in a 6-Month Randomised Controlled Trial: The MedLey Study. *Nutrients.* 2016; 8. <https://doi.org/10.3390/NU8090579> PMID: 27657119
  15. Djuric Z, Ren J, Blythe J, VanLoon G, Sen A. A Mediterranean dietary intervention in healthy American women changes plasma carotenoids and fatty acids in distinct clusters. *Nutr Res.* 2009; 29:156–163. <https://doi.org/10.1016/j.nutres.2009.03.001> PMID: 19358929
  16. Hagfors L, Leanderson P, Sköldstam L, Andersson J, Johansson G. Antioxidant intake, plasma antioxidants and oxidative stress in a randomized, controlled, parallel, Mediterranean dietary intervention study on patients with rheumatoid arthritis. *Nutr J.* 2003; 2:1–11. <https://doi.org/10.1186/1475-2891-2-5> PMID: 12952549
  17. Marin C, Ramirez R, Delgado-Lista J, Yubero-Serrano EM, Perez-Martinez P, Carracedo J, et al. Mediterranean diet reduces endothelial damage and improves the regenerative capacity of endothelium. *Am J Clin Nutr.* 2011; 93:267–274. Available from: <https://academic-oup-com.ezp.lib.cam.ac.uk/ajcn/article/93/2/267/4597613>. <https://doi.org/10.3945/ajcn.110.006866> PMID: 21123460
  18. Itsiopoulos C, Brazionis L, Kaimakamis M, Cameron M, Best JD, O'Dea K, et al. Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study. *Nutr Metab Cardiovasc Dis.* 2011; 21:740–747. <https://doi.org/10.1016/j.numecd.2010.03.005> PMID: 20674309
  19. Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F, Mamelle N, et al. Cretan Mediterranean diet for prevention of coronary heart disease. *Am J Clin Nutr.* 1995; 61:1360S–1367S. <https://doi.org/10.1093/ajcn/61.6.1360S> PMID: 7754988
  20. Mayneris-Perxachs J, Sala-Vila A, Chisaguano M, Castellote AI, Estruch R, Covas MI, et al. Effects of 1-year intervention with a Mediterranean diet on plasma fatty acid composition and metabolic syndrome in a population at high cardiovascular risk. *PLoS ONE.* 2014; 9:1–11. <https://doi.org/10.1371/journal.pone.0085202> PMID: 24651160
  21. Vincent-Baudry S, Defoort C, Gerber M, Bernard MC, Verger P, Helal O, et al. The Medi-RIVAGE study: Reduction of cardiovascular disease risk factors after a 3-mo intervention with a Mediterranean-type diet or a low-fat diet. *Am J Clin Nutr.* 2005; 82:964–971. <https://doi.org/10.1093/ajcn/82.5.964> PMID: 16280426
  22. Hagfors L, Nilsson I, Sköldstam L, Johansson G. Fat intake and composition of fatty acids in serum phospholipids in a randomized, controlled, Mediterranean dietary intervention study on patients with rheumatoid arthritis. *Nutr Metab.* 2005; 2:26. <https://doi.org/10.1186/1743-7075-2-26> PMID: 16216119
  23. Davis CR, Bryan J, Hodgson JM, Wilson C, Dhillion V, Murphy KJ. A randomised controlled intervention trial evaluating the efficacy of an Australianised Mediterranean diet compared to the habitual Australian diet on cognitive function, psychological wellbeing and cardiovascular health in healthy older adults (MedLey study): Protocol paper. *BMC Nutr.* 2015; 1:35. <https://doi.org/10.1186/s40795-015-0033-7>

24. Davis C, Hodgson J, Bryan J, Garg M, Woodman R, Murphy K. Older Australians Can Achieve High Adherence to the Mediterranean Diet during a 6 Month Randomised Intervention; Results from the Medley Study. *Nutrients*. 2017; 9:534. <https://doi.org/10.3390/nu9060534> PMID: 28538676
25. Lampe JW, Huang Y, Neuhauser ML, Tinker LF, Song X, Schoeller DA, et al. Dietary biomarker evaluation in a controlled feeding study in women from the Women's Health Initiative cohort. *Am J Clin Nutr*. 2017; 105:466–475. <https://doi.org/10.3945/ajcn.116.144840> PMID: 28031191
26. Pennant M, Steur M, Moore C, Butterworth A, Johnson L. Comparative validity of vitamin C and carotenoids as indicators of fruit and vegetable intake: a systematic review and meta-analysis of randomised controlled trials. *Br J Nutr*. 2015; 114:1331–1340. <https://doi.org/10.1017/S0007114515003165> PMID: 26349405
27. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res*. 2008; 47:348–380. <https://doi.org/10.1016/j.plipres.2008.03.003> PMID: 18435934
28. Song X, Huang Y, Neuhauser ML, Tinker LF, Vitolins MZ, Prentice RL, et al. Dietary long-chain fatty acids and carbohydrate biomarker evaluation in a controlled feeding study in participants from the Women's Health Initiative cohort. *Am J Clin Nutr*. 2017; 105:1272–1282. <https://doi.org/10.3945/ajcn.117.153072> PMID: 28446501
29. Lemaitre RN, King IB. Very long-chain saturated fatty acids and diabetes and cardiovascular disease. *Curr Opin Lipidol*. 2022; 33:76–82. <https://doi.org/10.1097/MOL.0000000000000806> PMID: 34907969
30. Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, Kerrison N, et al. Design and cohort description of the InterAct Project: An examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. *Diabetologia*. 2011; 54:2272–2282. <https://doi.org/10.1007/s00125-011-2182-9> PMID: 21717116
31. Barua AB, Kostic D, Olson JA. New simplified procedures for the extraction and simultaneous high-performance liquid chromatographic analysis of retinol, tocopherols and carotenoids in human serum. *J Chromatogr B Biomed Sci Appl*. 1993; 617:257–264. [https://doi.org/10.1016/0378-4347\(93\)80496-q](https://doi.org/10.1016/0378-4347(93)80496-q) PMID: 8408391
32. Tu WC, Mühlhäusler BS, Yelland LN, Gibson RA. Correlations between blood and tissue omega-3 LCPUFA status following dietary ALA intervention in rats. *Prostaglandins Leukot Essent Fat Acids*. 2013; 88:53–60. <https://doi.org/10.1016/j.plefa.2012.04.005> PMID: 22521090
33. Brevik A, Andersen LF, Karlsen A, Trygg KU, Blomhoff R, Drevon CA. Six carotenoids in plasma used to assess recommended intake of fruits and vegetables in a controlled feeding study. *Eur J Clin Nutr*. 2004; 58:1166–1173. <https://doi.org/10.1038/sj.ejcn.1601945> PMID: 15054430
34. Zheng JS, Sharp SJ, Imamura F, Chowdhury R, Gundersen TE, Steur M, et al. Association of plasma biomarkers of fruit and vegetable intake with incident type 2 diabetes: EPIC-InterAct case-cohort study in eight European countries. *BMJ*. 2020; 370. <https://doi.org/10.1136/bmj.m2194> PMID: 32641421
35. Wang L, Summerhill K, Rodriguez-Canas C, Mather I, Patel P, Eiden M, et al. Development and validation of a robust automated analysis of plasma phospholipid fatty acids for metabolic phenotyping of large epidemiological studies. *Genome Med*. 2013; 5:39. <https://doi.org/10.1186/gm443> PMID: 23618465
36. Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kröger J, Schulze MB, et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: The EPIC-InterAct case-cohort study. *Lancet Diabetes Endocrinol*. 2014; 2:810–818. [https://doi.org/10.1016/S2213-8587\(14\)70146-9](https://doi.org/10.1016/S2213-8587(14)70146-9) PMID: 25107467
37. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Public Health Nutr*. 2003; 6:407–413. <https://doi.org/10.1079/PHN2002439> PMID: 12795830
38. Riboli E, Hunt K, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr*. 2002; 5:1113. <https://doi.org/10.1079/PHN2002394> PMID: 12639222
39. Slimani N, Deharveng G, Unwin I, Southgate DAT, Vignat J, Skeie G, et al. The EPIC nutrient database project (ENDB): A first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. *Eur J Clin Nutr*. 2007; 61:1037–1056. <https://doi.org/10.1038/sj.ejcn.1602679> PMID: 17375121
40. Wei R, Wang J, Su M, Jia E, Chen S, Chen T, et al. Missing Value Imputation Approach for Mass Spectrometry-based Metabolomics Data. *Sci Rep*. 2018; 8. <https://doi.org/10.1038/s41598-017-19120-0> PMID: 29330539

41. Stryker WS, Kaplan LA, Stein EA, Stampfer MJ, Sober A, Willett WC. The relation of diet, cigarette smoking, and alcohol consumption to plasma beta-carotene and alpha-tocopherol levels. *Am J Epidemiol*. 1988; 127:283–296. <https://doi.org/10.1093/oxfordjournals.aje.a114804> PMID: 3257350
42. Zou H, Hastie T. Regularization and variable selection via the elastic net. *J R Stat Soc Ser B*. 2005; 67:301–320. <https://doi.org/10.1111/j.1467-9868.2005.00503.x>
43. Ounpraseuth S, Lensing SY, Spencer HJ, Kodell RL. Estimating misclassification error: A closer look at cross-validation based methods. *BMC Res Notes*. 2012; 5. <https://doi.org/10.1186/1756-0500-5-656> PMID: 23190936
44. Hoerl AE, Kennard RW. Ridge Regression: Applications to Nonorthogonal Problems. *Technometrics*. 1970; 12:69–82. <https://doi.org/10.1080/00401706.1970.10488635>
45. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*. 1982; 143:29–36. <https://doi.org/10.1148/radiology.143.1.7063747> PMID: 7063747
46. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. *Biometrika*. 1986; 73:1–11. <https://doi.org/10.1093/biomet/73.1.1>
47. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*. 2011; 342:964–967. <https://doi.org/10.1136/bmj.d549> PMID: 21310794
48. White IR. Multivariate random-effects meta-analysis. *Stata J*. 2009; 9:40–56. <https://doi.org/10.1177/1536867x0900900103>
49. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med*. 2011; 30:377–399. <https://doi.org/10.1002/sim.4067> PMID: 21225900
50. Seaman SR, Bartlett JW, White IR. Multiple imputation of missing covariates with non-linear effects and interactions: An evaluation of statistical methods. *BMC Med Res Methodol*. 2012; 12. <https://doi.org/10.1186/1471-2288-12-46> PMID: 22489953
51. Newson RB. Attributable and unattributable risks and fractions and other scenario comparisons. *Stata J*. 2013; 13:672–698. <https://doi.org/10.1177/1536867x1301300402>
52. Kalbfleisch JD, Lawless JF. Likelihood analysis of multi-state models for disease incidence and mortality. *Stat Med*. 1988; 7:149–160. <https://doi.org/10.1002/sim.4780070116> PMID: 3353602
53. Connolly SE. Beyond Parameter Estimation: Analysis of the Case-Cohort Design in Cox Models (Doctoral thesis). University of Cambridge; 2020. <https://doi.org/10.17863/CAM.51383>
54. Van Calster B, McLernon DJ, Van Smeden M, Wynants L, Steyerberg EW, Bossuyt P, et al. Calibration: The Achilles heel of predictive analytics. *BMC Med*. 2019; 17. <https://doi.org/10.1186/s12916-019-1466-7> PMID: 31842878
55. Nattino G, Lemeshow S, Phillips G, Finazzi S, Bertolini G. Assessing the calibration of dichotomous outcome models with the calibration belt. *Stata J*. 2017; 17:1003–1014. <https://doi.org/10.1177/1536867X1801700414>
56. Davis CR, Bryan J, Hodgson JM, Wilson C, Murphy KJ. Older Australians can adhere to a traditional Mediterranean style diet over two weeks: A pilot dietary intervention study. *BMC Nutr*. 2015; 1:1–10. <https://doi.org/10.1186/s40795-015-0021-y>
57. IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open*. 2016; 6:e010247. <https://doi.org/10.1136/bmjopen-2015-010247> PMID: 27406637
58. Guasch-Ferré M, Bhupathiraju SN, Hu FB. Use of Metabolomics in Improving Assessment of Dietary Intake. *Clin Chem*. 2018; 64:82–98. <https://doi.org/10.1373/clinchem.2017.272344> PMID: 29038146
59. Hidalgo-Liberona N, Meroño T, Zamora-Ros R, Rabassa M, Semba R, Tanaka T, et al. Adherence to the Mediterranean diet assessed by a novel dietary biomarker score and mortality in older adults: the InCHIANTI cohort study. *BMC Med*. 2021; 19. <https://doi.org/10.1186/s12916-021-02154-7> PMID: 34814922
60. Marklund M, Magnusdottir OK, Rosqvist F, Cloetens L, Landberg R, Kolehmainen M, et al. A Dietary Biomarker Approach Captures Compliance and Cardiometabolic Effects of a Healthy Nordic Diet in Individuals with Metabolic Syndrome. *J Nutr*. 2014; 144:1642–1649. <https://doi.org/10.3945/jn.114.193771> PMID: 25080537
61. Gerber M. Qualitative methods to evaluate Mediterranean diet in adults. *Public Health Nutr*. 2006; 9:147–151. <https://doi.org/10.1079/phn2005937> PMID: 16512962
62. Neuhouwer ML, Patterson RE, King IB, Horner NK, Lampe JW. Selected nutritional biomarkers predict diet quality. *Public Health Nutr*. 2003; 6:703–709. <https://doi.org/10.1079/phn2003486> PMID: 14552672
63. Medina-Remón A, Tresserra-Rimbau A, Pons A, Tur JA, Martorell M, Ros E, et al. Effects of total dietary polyphenols on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. *The*

- PREDIMED randomized trial. *Nutr Metab Cardiovasc Dis.* 2015; 25:60–67. <https://doi.org/10.1016/j.numecd.2014.09.001> PMID: 25315667
64. Li J, Guasch-Ferré M, Chung W, Ruiz-Canela M, Toledo E, Corella D, et al. The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. *Eur Heart J.* 2020;1–14. <https://doi.org/10.1093/eurheartj/ehaa209> PMID: 32406924
  65. Salas-Salvadó J, Bulló M, Estruch R, Ros E, Covas MI, Ibarrola-Jurado N, et al. Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial. *Ann Intern Med.* 2014; 160:1–10. <https://doi.org/10.7326/M13-1725> PMID: 24573661
  66. Roncero-Ramos I, Alcalá-Díaz JF, Rangel-Zuñiga OA, Gomez-Delgado F, Jimenez-Lucena R, García-Ríos A, et al. Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIO-PREV study. *Clin Nutr.* 2020; 39:492–500. <https://doi.org/10.1016/j.clnu.2019.02.027> PMID: 30852029
  67. de Koning L, Chiuve SE, Fung TT, Willett WC, Rimm EB, Hu FB. Diet-quality scores and the risk of type 2 diabetes in men. *Diabetes Care.* 2011; 34:1150–1156. <https://doi.org/10.2337/dc10-2352> PMID: 21464460
  68. Potischman N. Biologic and methodologic issues for nutritional biomarkers. *J Nutr.* 2003; 133:875S–880S. <https://doi.org/10.1093/jn/133.3.875S> PMID: 12612173
  69. Prentice RL, Huang Y. Nutritional epidemiology methods and related statistical challenges and opportunities. *Stat Theory Relat Fields.* 2018; 2:2–10. <https://doi.org/10.1080/24754269.2018.1466098> PMID: 30778402
  70. Jenab M, Slimani N, Bictash M, Ferrari P, Bingham SA. Biomarkers in nutritional epidemiology: Applications, needs and new horizons. *Hum Genet.* 2009; 125:507–525. <https://doi.org/10.1007/s00439-009-0662-5> PMID: 19357868
  71. Ferreri C, Masi A, Sansone A, Giacometti G, Larocca A, Menounou G, et al. Fatty Acids in Membranes as Homeostatic, Metabolic and Nutritional Biomarkers: Recent Advancements in Analytics and Diagnostics. *Diagnostics.* 2016; 7:1. <https://doi.org/10.3390/diagnostics7010001> PMID: 28025506
  72. Bell ML, Kenward MG, Fairclough DL, Horton NJ. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. *BMJ.* 2013;346. <https://doi.org/10.1136/bmj.e8668> PMID: 23338004
  73. Verbeek JH, Whaley P, Morgan RL, Taylor KW, Rooney AA, Schwingshackl L, et al. An approach to quantifying the potential importance of residual confounding in systematic reviews of observational studies: A GRADE concept paper. *Environ Int.* 2021; 157. <https://doi.org/10.1016/j.envint.2021.106868> PMID: 34530289
  74. Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses. *PLoS ONE.* 2018; 13:1–27. <https://doi.org/10.1371/journal.pone.0194127> PMID: 29558518
  75. Greenland S, Schlesselman JJ, Criqui MH. The fallacy of employing standardized regression coefficients and correlations as measures of effect. *Am J Epidemiol.* 1986; 123:203–208. <https://doi.org/10.1093/oxfordjournals.aje.a114229> PMID: 3946370
  76. Shi L, Brunius C, Johansson I, Bergdahl IA, Lindahl B, Hanhineva K, et al. Plasma metabolites associated with healthy Nordic dietary indexes and risk of type 2 diabetes—a nested case-control study in a Swedish population. *Am J Clin Nutr.* 2018; 108:564–575. <https://doi.org/10.1093/ajcn/nqy145> PMID: 30060042
  77. Trepanowski JF, Ioannidis JPA. Perspective: Limiting dependence on nonrandomized studies and improving randomized trials in human nutrition research: Why and how. *Adv Nutr.* 2018; 9:367–377. <https://doi.org/10.1093/advances/nmy014> PMID: 30032218